Shots:

• Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties & gets the option to take part in product development in exchange for higher royalty rates
• Post pre-clinical research and development activities- AbbVie has an option to license the program and proceed with IND-enabling studies- clinical development- and commercialization
• The collaboration leverages Caraway’s drug discovery platform- expertise in lysosomal biology & cellular clearance mechanisms combine with AbbVie’s expertise in disease biology- clinical development- and global commercialization

Ref: Business Wire | Image: Business Wire